An observational study in Lung Cancer, sponsored by AstraZeneca. Completed at 12 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-23.
Sponsored by AstraZeneca · Observational
The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population
A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 157 is below the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
hospital clinic
Exclusion Criteria:
Assessment of treatment duration, as a surrogate of Clinical Benefit (CB) in a 'Real World' population treated with gefitinib
Retrospective population \[2009 to 2013\]
Time frame: 6 months
Assessment of Overall Survival (OS) in a 'Real World' population treated with gefitinib
Retrospective population \[2009 to 2013\]
Time frame: 6 months
Assessment of Overall Survival (OS) in the subgroup of patients of Caucasian ethnicity and in the subgroup of patients treated with gefitinib for at least 3 months
Retrospective population \[2009 to 2013\]
Time frame: 6 months
Assessment of Treatment duration in the subgroup of patients of Caucasian ethnicity and in the subgroup of patients treated with gefitinib for at least 3 months
Retrospective population \[2009 to 2013\]
Time frame: 6 months
Characteristics of patients treated with gefitinib for all patients and stratified by whether gefitinib discontinued treatment before or after three months
Retrospective population \[2009 to 2013\]
Time frame: 6 months
Description of treatment patterns in patients treated with gefitinib (prior chemo, treatment breaks, treatment on discontinuation)
Retrospective population \[2009 to 2013\]
Time frame: 6 months
Duration of treatment in patients stratified by age, gender, stage and performance status.
Retrospective population \[2009 to 2013\]
Time frame: 6 months
Overall Survival (OS) in patients stratified by age, gender, stage and performance status.
Retrospective population \[2009 to 2013\]
Time frame: 6 months
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca